FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2760650159> ?p ?o ?g. }

• W2760650159 endingPage "12.e6" @default.
• W2760650159 startingPage "12.e1" @default.
• W2760650159 abstract "Previous pharmacologic studies demonstrated that higher sunitinib exposure is associated with improved clinical outcomes in patients with metastatic renal cell carcinoma (mRCC). We aimed to assess the efficacy and toxicity of sunitinib dose-escalation in mRCC patients progressing on the standard 50 mg dose. A single-institution retrospective review was conducted on mRCC patients, treated outside trials with a 50 mg sunitinib dose given on an individualized schedule between October 2009 and January 2016, who subsequently progressed on imaging. All progressing patients who were dose-escalated to 62.5 and 75 mg on an individualized schedule if toxicity permitted were eligible for this analysis. Median progression-free survival (PFS) and overall survival (OS) were analyzed using the Kaplan-Meier method. PFS1 and 2 were defined as the time between the start of sunitinib and first progression and the time between dose-escalation and second progression respectively. A total of 25 eligible patients were identified with a median follow-up of 40.3 months (Q1–Q3: 11.1–66.6) and a mean age of 54 years (standard deviation: 12.4). Most of the patients underwent cytoreductive surgery (92%) and were men (88%). In total 32%, 44%, and 24% had a good, intermediate, and poor prognostic Heng Score, respectively. At standard doses, 60% and 16% of patients had a partial response (PR) and a stable disease (SD) as best response respectively for a median duration of 11.4 months (95% CI: 3–20.7). A total of 6 patients (24%) had progressive disease as best response. After progression, 36% and 28% had PR and SD on higher doses of sunitinib respectively for a median duration of 7.8 months (95% CI: 6.3–12.4). The median PFS1, PFS2 and OS were 6.1 months (95% CI: 2.3–19.4), 6.7 months (95% CI: 3.1–8.4) and 63.7 months (95% CI: 26–NR) respectively. The most common adverse events after dose-escalation were fatigue (56%), diarrhea (40%) and skin toxicity (28%). Patients with mRCC who progress on 50 mg sunitinib dose, may derive a clinical benefit and prolonged survival from dose-escalation with acceptable toxicity profiles. These results need to be confirmed in prospective studies with the aim to overcome drug resistance and delay the change in systemic therapy at progression." @default.
• W2760650159 created "2017-10-06" @default.
• W2760650159 creator A5015792267 @default.
• W2760650159 creator A5061327271 @default.
• W2760650159 creator A5084099584 @default.
• W2760650159 date "2018-01-01" @default.
• W2760650159 modified "2023-10-02" @default.
• W2760650159 title "Sunitinib dose-escalation after disease progression in metastatic renal cell carcinoma" @default.
• W2760650159 cites W1518372007 @default.
• W2760650159 cites W1895933560 @default.
• W2760650159 cites W2019607817 @default.
• W2760650159 cites W2037794622 @default.
• W2760650159 cites W2044254728 @default.
• W2760650159 cites W2097955112 @default.
• W2760650159 cites W2099752220 @default.
• W2760650159 cites W2100669312 @default.
• W2760650159 cites W2113788015 @default.
• W2760650159 cites W2115125611 @default.
• W2760650159 cites W2116949558 @default.
• W2760650159 cites W2117125017 @default.
• W2760650159 cites W2117365333 @default.
• W2760650159 cites W2127786249 @default.
• W2760650159 cites W2130207513 @default.
• W2760650159 cites W2149456801 @default.
• W2760650159 cites W2153331460 @default.
• W2760650159 cites W2171369497 @default.
• W2760650159 cites W2337399251 @default.
• W2760650159 cites W2405961234 @default.
• W2760650159 cites W2569047031 @default.
• W2760650159 cites W4229769653 @default.
• W2760650159 doi "https://doi.org/10.1016/j.urolonc.2017.09.004" @default.
• W2760650159 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28966072" @default.
• W2760650159 hasPublicationYear "2018" @default.
• W2760650159 type Work @default.
• W2760650159 sameAs 2760650159 @default.
• W2760650159 citedByCount "11" @default.
• W2760650159 countsByYear W27606501592018 @default.
• W2760650159 countsByYear W27606501592019 @default.
• W2760650159 countsByYear W27606501592020 @default.
• W2760650159 countsByYear W27606501592021 @default.
• W2760650159 countsByYear W27606501592022 @default.
• W2760650159 crossrefType "journal-article" @default.
• W2760650159 hasAuthorship W2760650159A5015792267 @default.
• W2760650159 hasAuthorship W2760650159A5061327271 @default.
• W2760650159 hasAuthorship W2760650159A5084099584 @default.
• W2760650159 hasConcept C126322002 @default.
• W2760650159 hasConcept C126894567 @default.
• W2760650159 hasConcept C141071460 @default.
• W2760650159 hasConcept C143998085 @default.
• W2760650159 hasConcept C167135981 @default.
• W2760650159 hasConcept C2777288759 @default.
• W2760650159 hasConcept C2777472916 @default.
• W2760650159 hasConcept C2778822529 @default.
• W2760650159 hasConcept C2779134260 @default.
• W2760650159 hasConcept C2779490328 @default.
• W2760650159 hasConcept C2780739268 @default.
• W2760650159 hasConcept C29730261 @default.
• W2760650159 hasConcept C3019894029 @default.
• W2760650159 hasConcept C71924100 @default.
• W2760650159 hasConceptScore W2760650159C126322002 @default.
• W2760650159 hasConceptScore W2760650159C126894567 @default.
• W2760650159 hasConceptScore W2760650159C141071460 @default.
• W2760650159 hasConceptScore W2760650159C143998085 @default.
• W2760650159 hasConceptScore W2760650159C167135981 @default.
• W2760650159 hasConceptScore W2760650159C2777288759 @default.
• W2760650159 hasConceptScore W2760650159C2777472916 @default.
• W2760650159 hasConceptScore W2760650159C2778822529 @default.
• W2760650159 hasConceptScore W2760650159C2779134260 @default.
• W2760650159 hasConceptScore W2760650159C2779490328 @default.
• W2760650159 hasConceptScore W2760650159C2780739268 @default.
• W2760650159 hasConceptScore W2760650159C29730261 @default.
• W2760650159 hasConceptScore W2760650159C3019894029 @default.
• W2760650159 hasConceptScore W2760650159C71924100 @default.
• W2760650159 hasIssue "1" @default.
• W2760650159 hasLocation W27606501591 @default.
• W2760650159 hasLocation W27606501592 @default.
• W2760650159 hasOpenAccess W2760650159 @default.
• W2760650159 hasPrimaryLocation W27606501591 @default.
• W2760650159 hasRelatedWork W2070019048 @default.
• W2760650159 hasRelatedWork W2072245035 @default.
• W2760650159 hasRelatedWork W2154205092 @default.
• W2760650159 hasRelatedWork W2155196945 @default.
• W2760650159 hasRelatedWork W2415433510 @default.
• W2760650159 hasRelatedWork W2551353941 @default.
• W2760650159 hasRelatedWork W2767323531 @default.
• W2760650159 hasRelatedWork W3151554875 @default.
• W2760650159 hasRelatedWork W3152520552 @default.
• W2760650159 hasRelatedWork W4205243027 @default.
• W2760650159 hasVolume "36" @default.
• W2760650159 isParatext "false" @default.
• W2760650159 isRetracted "false" @default.
• W2760650159 magId "2760650159" @default.
• W2760650159 workType "article" @default.